Difference between revisions of "Team:Evry/Project/Chassis"

Line 29: Line 29:
 
<p class="text-justify">To address both safety and efficiency, we selected S. cerevisiae for the following advantages:</p>
 
<p class="text-justify">To address both safety and efficiency, we selected S. cerevisiae for the following advantages:</p>
  
<p class="text-justify"><strong>A.</strong>  S. cerevisiae is non pathogenic : phase I clinical trial with subcutaneous injection of heat-killed yeasts S. cerevisiae against hepatitis C showed no dose-related toxicity (14), demonstrating the safety of this vector for future human applications in cancer immunotherapy.</p>
+
<ul>
<p class="text-justify"><strong>B.</strong>  S. cerevisiae has a strong adjuvant effect, explaining why zymosan, an extract of S. cerevisiae cell wall, has been used to stimulate inflammation for 50 years (15). In particular, the mannose stimulate pro-inflammatory cytokines production in monocytes and dendritic cells, making the vector appropriate for APC targeting (16,17). </p>
+
<il><p class="text-justify"><strong>A.</strong>  S. cerevisiae is non pathogenic : phase I clinical trial with subcutaneous injection of heat-killed yeasts S. cerevisiae against hepatitis C showed no dose-related toxicity (14), demonstrating the safety of this vector for future human applications in cancer immunotherapy.</p></il>
<p class="text-justify"><strong>C.</strong>  S. cerevisiae already proved its anti-tumor capacity : the first demonstration of recombinant yeast to induce adaptative immunity was shown in 2001 by Stubbs et al against ovalbumin tumor cells (18). Yeast expressing the mutated RAS protein inside their cytosol induced reduction of lung tumors in mice and a quarter of the tumors were eradicated (19). Tumor antigen MART-1 was also expressed in yeast cytosol and induced both CD4+ and CD8+ in mice. (20)</p>
+
<il><p class="text-justify"><strong>B.</strong>  S. cerevisiae has a strong adjuvant effect, explaining why zymosan, an extract of S. cerevisiae cell wall, has been used to stimulate inflammation for 50 years (15). In particular, the mannose stimulate pro-inflammatory cytokines production in monocytes and dendritic cells, making the vector appropriate for APC targeting (16,17). </p></ill>
<p class="text-justify"><strong>D.</strong> S. cerevisiae prior immunization with the wild type do not create a response neutralizing the antigen expressing yeast, allowing repeated injections of the vector. (21)</p>
+
<il><p class="text-justify"><strong>C.</strong>  S. cerevisiae already proved its anti-tumor capacity : the first demonstration of recombinant yeast to induce adaptative immunity was shown in 2001 by Stubbs et al against ovalbumin tumor cells (18). Yeast expressing the mutated RAS protein inside their cytosol induced reduction of lung tumors in mice and a quarter of the tumors were eradicated (19). Tumor antigen MART-1 was also expressed in yeast cytosol and induced both CD4+ and CD8+ in mice. (20)</p></il>
 
+
<il><p class="text-justify"><strong>D.</strong> S. cerevisiae prior immunization with the wild type do not create a response neutralizing the antigen expressing yeast, allowing repeated injections of the vector. (21)</p></il>
 +
</ul>
  
  

Revision as of 00:13, 19 September 2015

Scroll to top To top